Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) introduced an enhanced digital version of its Labcorp Global Trial Connect™ platform, covering the Labcorp Sponsor™ and Labcorp Investigator™ portals. The redesign aims to improve visibility across clinical studies, simplify workflows and support faster decision-making for sponsors and investigator sites.
According to Labcorp, the upgrade was guided by feedback from more than 80 sponsors and 100 investigator sites. Key additions include a more intuitive, role-based interface; streamlined study management tools; embedded in-portal kit ordering that can reduce manual data entry by 75%; and a unified Study Oversight Dashboard integrating study, site, sample and supply insights.
The platform also adds a guided Report Wizard for customized reports and end-to-end sample lifecycle tracking. Labcorp positions these enhancements as part of ongoing digital investment within its Biopharma Laboratory Services business to support more efficient, high-quality clinical trial delivery.
Labcorp (NYSE: LH) announced that members of its executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept. 15, at 11:30 a.m. ET. A live audio webcast and a replay, available for 180 days, will be accessible through the Labcorp Investor Relations website.
Labcorp (NYSE: LH) announced it will offer the FDA-cleared Elecsys pTau-217 blood test, developed by Roche Diagnostics, to aid detection of amyloid pathology associated with Alzheimer’s disease in individuals aged 55+ who show signs, symptoms or complaints of cognitive decline.
Elecsys pTau-217 is described as the first and only FDA-cleared single-biomarker blood test that can both rule in and rule out amyloid pathology across primary and specialty care. The standardized assay uses the same clinically validated cutoffs in all settings and reports positive, intermediate and negative categories. According to Labcorp, performance is comparable to cerebrospinal fluid testing and PET imaging. Once ordered by a clinician, blood can be drawn in-office or at over 2,200 Labcorp patient service centers nationwide. The test will be available nationwide in the coming months and expands Labcorp’s Alzheimer’s testing portfolio, which already includes Elecsys pTau-181 and Lumipulse pTau-217/Beta-Amyloid 42 Ratio.
Labcorp (NYSE: LH) and the National Association of Community Health Centers (NACHC) announced a strategic alliance to support leadership development, practice improvement and community health across the U.S. Community Health Center (CHC) network, which includes 1,526 CHCs serving 52.3 million patients.
The collaboration includes launching the NACHC Leadership Exchange for Chief Medical Officers, a program created by NACHC with Labcorp’s subject matter support to build leadership, operational and clinical capabilities of current and emerging clinical leaders. The alliance will also focus on educational initiatives, practice improvement, evidence generation and the use of de-identified Labcorp data to strengthen quality performance, close gaps in care and improve patient outcomes.
Labcorp (NYSE: LH) announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET. Chairman and CEO Adam Schechter, EVP and CFO Julia Wang and other executives will present the company’s go-forward strategy, capital deployment priorities and long-term financial outlook, followed by a Q&A session. A live webcast and replay with supporting materials will be accessible via the Labcorp Investor Relations website.
Labcorp (NYSE: LH) announced that the U.S. Food and Drug Administration has approved its PGDx elio® tissue complete CDx as a companion diagnostic for patients with advanced melanoma.
The test helps identify patients whose tumors harbor specific BRAF V600E/K variants, indicating they may benefit from FDA‑approved BRAF inhibitor and BRAF/MEK inhibitor combination therapies. According to Labcorp, melanoma is the deadliest form of skin cancer, and targeted therapies are an important option for stage IV patients with BRAF alterations. The kit‑based CDx can be used by qualified healthcare professionals across hospitals and clinical laboratories, enabling institutions to implement testing on‑site, retain samples and data, and potentially support future clinical research. This approval also expands Labcorp’s precision medicine portfolio of tissue‑ and liquid‑based oncology diagnostics designed to support personalized care.
Labcorp (NYSE: LH) announced nationwide availability of Roche's VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic to determine PTEN protein loss in tumors from patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for combination treatment with AstraZeneca's TRUQAP (capivasertib), abiraterone acetate and prednisone.
According to Labcorp, the test is now offered through its national laboratory network, expanding access to FDA-approved companion diagnostics and supporting precision oncology by providing PTEN biomarker information to guide personalized prostate cancer treatment decisions.
Labcorp (NYSE: LH) reported 2026 Q2 revenue of $3.73 billion, up 5.8% year over year, with operating margin rising to 12.1% and adjusted operating margin to 15.8%. Diluted EPS was $3.64 vs. $2.84, and adjusted EPS was $4.99 vs. $4.35.
Diagnostics revenue grew 5.5% with 18.0% adjusted operating margin, while Biopharma Laboratory Services revenue rose 6.5% and margin reached 17.0%. Labcorp raised 2026 enterprise revenue growth guidance to 5.4%–6.3% and adjusted EPS to $18.10–$18.55. The company added $1.0 billion to its share repurchase authorization (total remaining $1.4 billion), maintained a quarterly dividend of $0.72 per share, and highlighted oncology test launches, consumer health offerings, expanded Epic integration, and a Biopharma backlog of $8.73 billion.
Labcorp (NYSE: LH) announced the launch of the Marker by Labcorp™ Genetic Health Panel, a consumer-focused test analyzing 163 genes associated with hereditary cancer, cardiovascular and metabolic conditions linked to more than 100 medically actionable health conditions. The panel is offered through Labcorp OnDemand and includes access to licensed genetic counselors for result interpretation and next-step guidance.
According to Labcorp, consumers purchase the test online, complete a blood draw at one of over 2,200 patient service centers, and receive results via Labcorp’s secure portal and MyLabcorp AI-powered mobile platform. The service integrates clinical genetic testing, specimen collection and counseling into a single experience and will be available starting August 3, 2026.
Labcorp (NYSE: LH) announced that its board declared a quarterly cash dividend of $0.72 per share on common stock. The dividend is payable on September 11, 2026 to shareholders of record at the close of business on August 28, 2026.